<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://conterapharma.com/wp-sitemap.xsl" ?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"><url><loc>https://conterapharma.com/2011/05/18/concit-pharma-raises-new-capital/</loc><lastmod>2026-10-23T11:43:10+00:00</lastmod></url><url><loc>https://conterapharma.com/2012/06/12/concit-pharma-raises-new-capital-2/</loc><lastmod>2026-10-23T11:47:26+00:00</lastmod></url><url><loc>https://conterapharma.com/2012/10/02/concit-pharma-and-copenhagen-university-starts-joint-project/</loc><lastmod>2026-10-23T11:49:36+00:00</lastmod></url><url><loc>https://conterapharma.com/2013/06/10/concit-pharma-presents-jm-010-at-sydney-meeting/</loc><lastmod>2026-10-23T11:50:59+00:00</lastmod></url><url><loc>https://conterapharma.com/2013/07/12/concit-pharma-recieves-approval-to-start-phase-iia-study/</loc><lastmod>2026-10-23T11:52:25+00:00</lastmod></url><url><loc>https://conterapharma.com/2013/10/06/concit-pharma-in-ny/</loc><lastmod>2026-10-23T11:53:13+00:00</lastmod></url><url><loc>https://conterapharma.com/2013/12/14/contera-pharma-new-name-and-organisation/</loc><lastmod>2026-10-23T11:54:20+00:00</lastmod></url><url><loc>https://conterapharma.com/2014/11/28/bukwang-pharmaceuticals-acquires-contera-pharma/</loc><lastmod>2026-10-23T12:04:51+00:00</lastmod></url><url><loc>https://conterapharma.com/2015/05/01/solural-pharma-and-contera-pharma-initiate-eurostar-sponsored-project-in-parkinsons-disease/</loc><lastmod>2026-10-23T12:04:18+00:00</lastmod></url><url><loc>https://conterapharma.com/2015/06/15/press-release-jm-010cs01-phase-iia-cpoc-study/</loc><lastmod>2026-10-23T12:14:12+00:00</lastmod></url><url><loc>https://conterapharma.com/2015/11/06/us-patent-covering-jm-010-for-treatment-of-movement-disorders-has-been-granted/</loc><lastmod>2026-10-28T14:05:24+00:00</lastmod></url><url><loc>https://conterapharma.com/2016/09/07/press-release-jm-010cs01-phase-iia-cpoc-study-2/</loc><lastmod>2026-10-28T14:08:22+00:00</lastmod></url><url><loc>https://conterapharma.com/2017/01/05/bukwang-pharmaceutical-co-ltd-lid-treatment-jm-010-is-approved-for-orphan-drug-designation/</loc><lastmod>2026-11-19T10:19:32+00:00</lastmod></url><url><loc>https://conterapharma.com/2018/01/31/bukwang-pharmaceutical-co-ltd-bukwang-registered-patents-on-a-therapeutic-candidate-for-levodopa-induced-dyskinesia-in-parkinsons-disease-international-applic/</loc><lastmod>2026-11-19T07:28:28+00:00</lastmod></url><url><loc>https://conterapharma.com/2018/10/22/bukwang-announces-approval-of-clinical-trial-application-by-european-authority-to-initiate-phase-2-study-of-jm-010/</loc><lastmod>2026-11-19T07:31:29+00:00</lastmod></url><url><loc>https://conterapharma.com/2019/06/26/bukwang-announced-commencement-of-phase-2-clinical-study-of-jm-010-in-major-european-countries/</loc><lastmod>2026-11-19T07:32:30+00:00</lastmod></url><url><loc>https://conterapharma.com/2019/07/10/contera-pharma-a-subsidiary-of-bukwang-pharmaceutical-attracts-investment-from-medici-investment/</loc><lastmod>2026-11-19T10:18:00+00:00</lastmod></url><url><loc>https://conterapharma.com/2020/01/10/bukwang-initiates-dosing-of-jm-010-in-europe-phase-2-study/</loc><lastmod>2026-11-19T10:18:50+00:00</lastmod></url><url><loc>https://conterapharma.com/2020/02/14/bukwang-receives-us-fda-approval-for-jm-010-phase-2-clinical-study-ind/</loc><lastmod>2026-10-28T14:17:19+00:00</lastmod></url><url><loc>https://conterapharma.com/2020/04/01/contera-pharma-opens-office-in-seoul-korea/</loc><lastmod>2026-10-28T14:17:46+00:00</lastmod></url><url><loc>https://conterapharma.com/2020/07/22/contera-pharma-subsidiary-of-bukwang-raises-51-billion-krw-in-series-b-financing-round/</loc><lastmod>2026-10-28T14:18:33+00:00</lastmod></url><url><loc>https://conterapharma.com/2020/12/01/contera-pharma-elected-new-executive-management-team/</loc><lastmod>2026-10-28T14:19:09+00:00</lastmod></url><url><loc>https://conterapharma.com/2021/07/07/abzu-and-contera-pharma-partner-to-design-rna-therapeutics-for-rare-diseases-using-xai-technology/</loc><lastmod>2026-10-28T14:20:57+00:00</lastmod></url><url><loc>https://conterapharma.com/2022/09/08/contera-pharma-signs-agreement-with-bdd-pharma-for-development-of-a-novel-tablet-formulation-to-treat-nocturnal-symptoms-and-morning-akinesia-in-parkinsons-disease/</loc><lastmod>2026-11-19T10:16:58+00:00</lastmod></url><url><loc>https://conterapharma.com/2022/09/27/vernalis-research-a-fully-owned-subsidiary-of-hitgen-inc-and-contera-pharma-a-s-announce-a-strategic-collaboration-in-the-field-of-rna-targeting-small-molecules-in-neurology/</loc><lastmod>2026-11-19T10:16:26+00:00</lastmod></url><url><loc>https://conterapharma.com/2023/04/11/abzu-and-contera-pharma-expand-strategic-partnership-to-add-target-identification-to-rna-therapeutic-design-platform/</loc><lastmod>2026-10-28T14:23:58+00:00</lastmod></url><url><loc>https://conterapharma.com/2023/09/27/contera-pharma-and-bdd-pharma-announce-dosing-of-first-subject-in-a-phase-1-trial-of-cp-012-a-novel-formulation-to-treat-nocturnal-symptoms-and-morning-akinesia-in-parkinsons-disease/</loc><lastmod>2026-11-19T10:15:11+00:00</lastmod></url><url><loc>https://conterapharma.com/2024/01/17/last-patient-enrolled-in-the-astoria-phase-2b-clinical-trial-evaluating-jm-010-an-innovative-therapy-to-treat-parkinsons-disease-dyskinesia/</loc><lastmod>2026-11-19T10:14:12+00:00</lastmod></url><url><loc>https://conterapharma.com/2024/05/21/contera-pharma-reports-topline-results-from-its-phase-iib-clinical-trial-astoria-evaluating-jm-010-for-treatment-of-parkinsons-disease-dyskinesia/</loc><lastmod>2026-11-19T10:13:38+00:00</lastmod></url><url><loc>https://conterapharma.com/2024/09/06/contera-pharma-announces-management-changes-to-secure-progression-of-lead-programs-and-further-expansion-of-pipeline/</loc><lastmod>2026-11-19T10:07:04+00:00</lastmod></url><url><loc>https://conterapharma.com/2024/09/23/contera-pharma-a-s-closes-korean-office-and-consolidates-all-activities-in-denmark/</loc><lastmod>2026-10-28T14:30:04+00:00</lastmod></url><url><loc>https://conterapharma.com/2024/10/18/contera-pharma-a-s-closes-korean-office-and-consolidates-all-activities-in-denmark-2nd-announcement/</loc><lastmod>2026-10-28T14:30:50+00:00</lastmod></url><url><loc>https://conterapharma.com/2024/11/28/contera-pharma-announces-first-patient-dosed-in-phase-1b-trial-of-cp-012-a-novel-therapy-to-treat-nocturnal-immobility-and-morning-akinesia-in-parkinsons-disease/</loc><lastmod>2026-11-19T10:06:17+00:00</lastmod></url><url><loc>https://conterapharma.com/2024/12/03/contera-pharma-welcomes-new-board-members-to-drive-strategic-growth/</loc><lastmod>2026-11-19T10:05:52+00:00</lastmod></url><url><loc>https://conterapharma.com/2025/03/14/contera-pharma-announces-that-cp0014753-a-novel-antisense-oligonucleotide-developed-for-the-treatment-of-canavan-disease-is-ready-for-ind-enabling-studies/</loc><lastmod>2026-11-19T10:04:23+00:00</lastmod></url><url><loc>https://conterapharma.com/2025/08/28/contera-pharma-announces-last-patient-dosed-in-phase-1b-trial-of-cp-012-a-novel-therapy-to-treat-nocturnal-symptoms-and-morning-akinesia-in-parkinsons-disease/</loc><lastmod>2026-11-19T10:10:26+00:00</lastmod></url><url><loc>https://conterapharma.com/2025/09/17/contera-pharma-announces-positive-topline-results-in-phase-1b-trial-of-cp-012-a-novel-therapy-to-treat-nocturnal-immobility-and-morning-akinesia-in-parkinsons-disease/</loc><lastmod>2026-11-20T12:16:53+00:00</lastmod></url><url><loc>https://conterapharma.com/2025/10/20/lundbeck-and-contera-pharma-announce-research-collaboration-to-advance-rna-targeting-medicines-for-serious-neurological-conditions/</loc><lastmod>2026-11-16T11:47:44+00:00</lastmod></url></urlset>
